The leucine-rich glioma inactivated -1 gene is rearranged as a result of translocations in glioblastoma cell lines. The protein contains a hydrophobic segment representing a putative transmembrane domain with the amino terminus located outside the cell. It also contains leucine-rich repeats with conserved cysteine-rich flanking sequences. This gene is predominantly expressed in neural tissues and its expression is reduced in low grade brain tumors and significantly reduced or absent in malignant gliomas.[1]
Clinical significance
Since its earliest discovery, the LGI1 gene has been implicated in the control of cancer metastasis and in a predisposition to epilepsy. Following genetic linkage studies placing the hereditary form of autosomal dominant partial epilepsy with Auditory features (ADPEAF) on chromosome region 10q24[2][3] mutation analysis of affected members in these families[4][5] demonstrated LGI1 was the cause of the disease.
More recently, LGI1 has been shown to be the major target of human autoantibodies[6][7][8] which immunoprecipitate voltage-gated potassium channel complexes from mammalian brain tissue. LGI1 antibodies are found in patients with limbic encephalitis and in patients with faciobrachial dystonic seizures (FBDS) FBDS are a recently described epilepsy which is characterised by frequent, brief seizures which affect the arm and face. They appear to be preferentially responsive to immunotherapy over anti-epileptic drugs.
↑Wilson MH, Puranam RS, Ottman R, Gilliam C, Limbird LE, George AL, McNamara JO (Dec 1998). "Evaluation of the alpha(2A)-adrenergic receptor gene in a heritable form of temporal lobe epilepsy". Neurology. 51 (6): 1730–1. doi:10.1212/wnl.51.6.1730. PMID9855534.
↑Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, Pettingill R, Waters P, Thomas A, Voets NL, Cardoso MJ, Cash DM, Manning EN, Lang B, Smith SJ, Vincent A, Johnson MR (Oct 2013). "Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype". Brain. 136 (Pt 10): 3151–62. doi:10.1093/brain/awt212. PMID24014519.
↑Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, S Zagami A, Bleasel A, Somerville ER, Smith SM, Vincent A (May 2011). "Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis". Annals of Neurology. 69 (5): 892–900. doi:10.1002/ana.22307. PMID21416487.
↑ 9.09.1Fukata Y, Adesnik H, Iwanaga T, Bredt DS, Nicoll RA, Fukata M (Sep 2006). "Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission". Science. 313 (5794): 1792–5. doi:10.1126/science.1129947. PMID16990550.
Further reading
Staub E, Pérez-Tur J, Siebert R, Nobile C, Moschonas NK, Deloukas P, Hinzmann B (Sep 2002). "The novel EPTP repeat defines a superfamily of proteins implicated in epileptic disorders". Trends in Biochemical Sciences. 27 (9): 441–4. doi:10.1016/S0968-0004(02)02163-1. PMID12217514.
Gu W, Brodtkorb E, Piepoli T, Finocchiaro G, Steinlein OK (May 2005). "LGI1: a gene involved in epileptogenesis and glioma progression?". Neurogenetics. 6 (2): 59–66. doi:10.1007/s10048-005-0216-5. PMID15827762.
Chernova OB, Somerville RP, Cowell JK (Dec 1998). "A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors". Oncogene. 17 (22): 2873–81. doi:10.1038/sj.onc.1202481. PMID9879993.
Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, Sáenz A, Poza JJ, Galán J, Gesk S, Sarafidou T, Mautner VF, Binelli S, Staub E, Hinzmann B, French L, Prud'homme JF, Passarelli D, Scannapieco P, Tassinari CA, Avanzini G, Martí-Massó JF, Kluwe L, Deloukas P, Moschonas NK, Michelucci R, Siebert R, Nobile C, Pérez-Tur J, López de Munain A (May 2002). "Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy". Human Molecular Genetics. 11 (9): 1119–28. doi:10.1093/hmg/11.9.1119. PMID11978770.
Scheel H, Tomiuk S, Hofmann K (Jul 2002). "A common protein interaction domain links two recently identified epilepsy genes". Human Molecular Genetics. 11 (15): 1757–62. doi:10.1093/hmg/11.15.1757. PMID12095917.
Gu W, Brodtkorb E, Steinlein OK (Sep 2002). "LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures". Annals of Neurology. 52 (3): 364–7. doi:10.1002/ana.10280. PMID12205652.
Pizzuti A, Flex E, Di Bonaventura C, Dottorini T, Egeo G, Manfredi M, Dallapiccola B, Giallonardo AT (Mar 2003). "Epilepsy with auditory features: a LGI1 gene mutation suggests a loss-of-function mechanism". Annals of Neurology. 53 (3): 396–9. doi:10.1002/ana.10492. PMID12601709.
Fertig E, Lincoln A, Martinuzzi A, Mattson RH, Hisama FM (May 2003). "Novel LGI1 mutation in a family with autosomal dominant partial epilepsy with auditory features". Neurology. 60 (10): 1687–90. doi:10.1212/01.wnl.0000063324.39980.4a. PMID12771268.
Kunapuli P, Chitta KS, Cowell JK (Jun 2003). "Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene". Oncogene. 22 (26): 3985–91. doi:10.1038/sj.onc.1206584. PMID12821932.
Hedera P, Abou-Khalil B, Crunk AE, Taylor KA, Haines JL, Sutcliffe JS (Mar 2004). "Autosomal dominant lateral temporal epilepsy: two families with novel mutations in the LGI1 gene". Epilepsia. 45 (3): 218–22. doi:10.1111/j.0013-9580.2004.47203.x. PMID15009222.
Kunapuli P, Kasyapa CS, Hawthorn L, Cowell JK (May 2004). "LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway". The Journal of Biological Chemistry. 279 (22): 23151–7. doi:10.1074/jbc.M314192200. PMID15047712.
Bisulli F, Tinuper P, Scudellaro E, Naldi I, Bagattin A, Avoni P, Michelucci R, Nobile C (Sep 2004). "A de novo LGI1 mutation in sporadic partial epilepsy with auditory features". Annals of Neurology. 56 (3): 455–6. doi:10.1002/ana.20218. PMID15349881.